Frontiers in Oncology (May 2022)
Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
- Lu Zhao,
- Lu Zhao,
- Qingyun Mei,
- Qingyun Mei,
- Yongchao Yu,
- Yongchao Yu,
- Na Wang,
- Na Wang,
- Dou Zhang,
- Dou Zhang,
- Dongying Liao,
- Dongying Liao,
- Jinhui Zuo,
- Jinhui Zuo,
- Hongxia Xie,
- Hongxia Xie,
- Yingjie Jia,
- Yingjie Jia,
- Fanming Kong,
- Fanming Kong
Affiliations
- Lu Zhao
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Lu Zhao
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Qingyun Mei
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Qingyun Mei
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Yongchao Yu
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Yongchao Yu
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Na Wang
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Na Wang
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Dou Zhang
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Dou Zhang
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Dongying Liao
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Dongying Liao
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Jinhui Zuo
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Jinhui Zuo
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Hongxia Xie
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Hongxia Xie
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Yingjie Jia
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Yingjie Jia
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- Fanming Kong
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Fanming Kong
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
- DOI
- https://doi.org/10.3389/fonc.2022.894214
- Journal volume & issue
-
Vol. 12
Abstract
Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.
Keywords
